CMS Proposes 55% Payment Increase for Prostatic Stent and Major Urology ASC Expansion in 2027

QUICK ANSWER

• What are the 2027 OPPS changes for urology billing? As of July 2, 2026, the CMS 2027 OPPS proposed rule (CMS-1850-P) includes a 55 percent payment increase for CPT 52282 (cystourethroscopy with insertion of a permanent prostatic urethral stent) by reassigning the code from APC 5374 to APC 5375, raising the proposed hospital outpatient payment from $4,064 to $6,292. The rule also proposes removing urinary and male genital procedures from the Inpatient Only list and expanding the ASC covered procedures list by 618 procedures, with urology named as a key surgical specialty in the expansion.
• CPT 52282 moves to a higher-paying APC. CMS analyzed 2025 claims data and determined the procedure’s resource costs justify reassignment from Level 4 to Level 5 Urology Services.
• Urinary and male genital procedures are leaving the IPO list. As part of the three-year IPO phase-out, 638 procedures across multiple clinical families, including urinary and male genital, are proposed for removal in 2027.
• The ASC covered procedures list is expanding. CMS proposes adding 618 procedures to the ASC CPL, giving urologists more options for where to perform and bill Medicare-covered procedures.

What CMS Proposed on July 2

CMS released the CY 2027 OPPS/ASC proposed rule (CMS-1850-P) on July 2, 2026. For urology practices, three provisions stand out. The CPT 52282 APC reassignment is the most direct payment change. CMS evaluated Medicare outpatient department claims for permanent prostatic stent insertion from January through December 2025 and concluded that the procedure’s resource utilization aligns with APC 5375 (Level 5 Urology and Related Services) rather than APC 5374 (Level 4). The American Urological Association highlighted this change in its summary of the proposed rule, noting the payment would increase from $4,064 to $6,292, a 55 percent increase for hospital outpatient settings.

The IPO list removal is the broader structural change. CMS is in year two of a three-year phase-out of the entire Inpatient Only list, which historically restricted certain procedures to inpatient hospital billing only. For 2027, CMS proposes removing 638 procedures, including those in the urinary and male genital clinical families. Once removed, these procedures become billable in either the inpatient or hospital outpatient setting, depending on clinical appropriateness. The remaining 801 procedures, which CMS considers more clinically complex, would move off the list in the final transition year (2028).

The ASC expansion adds 618 procedures to the covered procedures list, with urology named alongside general surgery, ENT, gynecology, and pulmonary/thoracic surgery as the key surgical specialties affected. For urology practices operating in or affiliated with ASCs, this creates new billing opportunities for procedures that were previously restricted to hospital settings. For practices evaluating whether to perform cystoscopy procedures in an ASC setting, the expanded list may include additional endoscopic and minor surgical urology codes.

Does This Affect My Urology Practice?

If your practice bills Medicare for urology procedures performed in a hospital outpatient department or an ASC, these changes directly affect your reimbursement and your site-of-service decisions. The CPT 52282 payment increase applies to hospital outpatient billing. The IPO list removal opens outpatient billing for procedures that were previously inpatient-only. The ASC expansion creates new ASC billing options.

The practices most affected are those that perform a mix of office-based, hospital outpatient, and ASC procedures. The site-of-service decision for each procedure now carries a reimbursement consequence that did not exist when the procedure was restricted to one setting. Across the billing companies we vet for urology practices, the most common revenue leak we see is practices that do not evaluate site-of-service payment differences when procedures move between settings. A procedure that pays well in the hospital outpatient department may pay less in an ASC, or vice versa. The billing team needs to model both rates before the practice commits to a service location.

For practices that perform prostatic stent placement in the hospital outpatient setting, the 55 percent payment increase on CPT 52282 is significant. At a payment of $6,292 per procedure in the proposed APC 5375, each case generates substantially more revenue than under the current APC 5374 rate of $4,064. That is an additional $2,228 per procedure if finalized.

How Do the IPO List and ASC Changes Affect Urology Revenue?

The IPO list removal creates a billing choice that did not previously exist. When a urological procedure is on the IPO list, Medicare only pays for it as an inpatient hospital stay under DRG-based payment. Once the procedure is removed from the IPO list, it becomes payable in the hospital outpatient setting under OPPS APC-based payment and, if added to the ASC covered procedures list, in ambulatory surgical centers under ASC-based payment.

The revenue impact depends on the specific procedure and setting. Hospital outpatient rates under OPPS are generally higher than ASC rates for the same CPT code. However, ASC settings typically have lower overhead and faster throughput, which can improve overall profitability even at a lower per-procedure reimbursement. The table below illustrates how the payment framework changes for urology procedures moving off the IPO list.

What Should Urology Practices Do Before January 2027?

The rule is proposed, not finalized. The comment period closes August 31, 2026. But the direction is clear, and billing teams should prepare now.

• Identify which of your procedures are moving off the IPO list. Review the proposed removal list against your practice’s procedure volume. For every procedure your urologists currently perform as inpatient-only, determine whether outpatient or ASC billing would be clinically and financially appropriate.
• Model the payment difference by setting for each affected procedure. Compare the current DRG payment to the proposed OPPS APC rate and, where applicable, the ASC rate. The setting with the highest net reimbursement after overhead is not always the hospital outpatient department.
• Update your CPT 52282 revenue projections. If your practice performs prostatic stent placement in the hospital outpatient setting, the proposed APC reassignment from 5374 to 5375 increases payment by $2,228 per procedure. Factor this into your 2027 budget if the rule is finalized.
• Review your ASC agreements. If your urologists operate in or have access to an ASC, confirm which newly eligible procedures you plan to perform there and whether your ASC payer contracts cover those codes. Payer contracts may need amendments to include newly ASC-eligible procedures.
• Check whether your billing system handles multi-site urology coding correctly. Billing the same CPT code in different settings requires different payment expectations, different modifier usage, and in some cases different prior authorization workflows. Your billing team or billing company should verify that the system applies the correct rates by site of service.
• Submit comments to CMS by August 31, 2026. The AUA is coordinating comments for the specialty. If the proposed changes affect your practice, participating in the comment process helps ensure the final rule reflects real-world urology practice patterns.

Common Site-of-Service Billing Mistakes

Providers often come to us after losing revenue because their billing team did not adjust workflows when procedures moved between settings. These are the most common errors.

• Billing the hospital outpatient rate when the procedure was performed in an ASC. Each setting has its own payment rate for the same CPT code. Submitting a claim with the wrong place-of-service code results in either a denial or an incorrect payment that will be recouped later.
• Not updating prior authorization workflows for newly outpatient-eligible procedures. When a procedure moves off the IPO list, the prior authorization requirements may change. Payers that did not require prior auth for the inpatient version may require it for the outpatient version, or vice versa. Your billing team needs to verify authorization requirements per payer for each affected code.
• Assuming the Two-Midnight Rule applies to newly removed procedures. CMS has proposed exempting procedures removed from the IPO list from Two-Midnight Rule compliance review during the transition period. However, this exemption does not mean the clinical documentation can be weaker. Your operative notes still need to support the medical necessity of the procedure regardless of setting.
• Not updating the bilateral procedure modifier logic for procedures moving to new settings. Modifier 50 (bilateral procedure) reimbursement rules differ between inpatient DRG payment and outpatient APC payment. If your urologists perform bilateral procedures that are moving off the IPO list, your billing team needs to verify how the modifier is applied under OPPS and ASC payment rules.

CPT codes and descriptors are maintained by the American Medical Association and are provided here for reference. Bundling, modifier, and global-period rules vary by payer and by Medicare contractor, so verify against current CPT guidelines, the current NCCI edit file, and payer policies before billing.

Frequently Asked Questions

Next Steps

Start by reviewing the CMS-1850-P proposed rule addenda to identify which urology procedures your practice performs that are affected by the IPO list removal and ASC expansion. Model the payment differences by setting for each affected code.

If your billing team needs help navigating site-of-service payment differences, APC reassignments, or the 2027 OPPS changes specific to urology, Urology Bill Co connects you with billing companies that specialize in urology coding and reimbursement across all practice settings.